Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 585 participants.

Also called NCT06676384

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 585 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06676384
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
India (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06676384. Randomized; single masking; primary purpose treatment. Start 2025-02-15 (actual); primary completion 2029-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Acronym
IA-GRACE-IgANT
Condition
IgA Nephropathy
Condition
Renal Insufficiency, Chronic
Condition
IgA Vasculitis
Condition
IGA Glomerulonephritis
Intervention (Drug)
Oral prednisolone and SoC
Intervention (Drug)
Gut-directed budesonide and SoC
Intervention (Drug)
Mycophenolate mofetil (MMF) and SoC
Intervention (Drug)
Hydroxychloroquine and SoC
Intervention (Drug)
Non-steroidal mineralocorticoid receptor antagonist and SoC
Intervention (Drug)
SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)
Lead sponsor
Christian Medical College, Vellore, India (class: other)
Collaborator
Medical Research Council (class: other government)
Collaborator
India Alliance (class: not stated)

Record details

Record id
cardio:ct-nct06676384
Content hash
f404a2a63593cabbc9d15645e967a0ffdb64ac03a2e48c32cb6bc581899c7bf9